Meticulous Research®, a leading global market research firm, has released its latest report titled, “Europe Single-use Bioreactors Market by Product [Systems, Media Bags (2D, 3D), Filtration Assemblies], Type [Stirred Tank, Wave Induced], Cell [Mammalian, Bacterial, Yeast], Application [Commercial (Mab, Vaccine), Research], End User – Forecast to 2030.”

Download Sample Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5552

According to the report, the Europe single-use bioreactors market is projected to reach $3.34 billion by 2030, growing at a CAGR of 15.3% during the forecast period. The increasing adoption of disposable technologies in pharmaceutical and biotechnology sectors, capacity expansions in biopharmaceutical manufacturing, rising pharmaceutical R&D spending, and the growing prevalence of chronic diseases due to an aging population are driving the market’s growth.

Europe Single-use Bioreactors Market: Future Outlook
The report segments the market by product, type, cell type, application, end user, and geography. It provides a detailed analysis of industry competitors and assesses market shares at the country level.

• By Product: The market is segmented into single-use bioreactor systems, media bags, filtration assemblies, and other products. In 2024, single-use bioreactor systems are expected to hold the largest share, driven by benefits such as reduced cleaning requirements, increased flexibility, smaller footprint, lower capital investment, and minimized risk of cross-contamination. The demand from biopharma companies aiming to reduce costs further fuels the growth of this segment.

Browse In Depth: https://www.meticulousresearch.com/product/europe-single-use-bioreactors-market-5552

• By Type: The stirred-tank bioreactors segment is projected to dominate in 2024, owing to their extensive use for CHO cell lines and suspension cultures in large-volume bioproduction. Their advanced designs over traditional systems also contribute to their growth.

• By Cell Type: The mammalian cells segment is expected to account for the largest share in 2024. Mammalian cells are widely used in both commercial and research bioproduction, especially for developing complex biomolecules like monoclonal antibodies and therapeutic proteins. Their extensive use in clinical research further supports market growth.

• By Application: The commercial bio-production segment is expected to dominate in 2024, driven by the increasing production of biosimilars, rising cases of genetic and rare diseases, and government support for vaccine development and immunization programs.

• By End User: Contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) are expected to register the highest CAGR during the forecast period. This growth is attributed to the growing trend of outsourcing by pharmaceutical and biopharmaceutical companies, along with CDMOs’ expansion strategies. For example, in July 2021, Viralgen VC (Spain) launched a new facility in Basque, Italy, focused on adeno-associated virus gene therapy production.

Geographic Insights
The report analyzes key regions and countries across Europe, including Germany, France, the U.K., Italy, Spain, Switzerland, Ireland, Denmark, Belgium, and the Rest of Europe. In 2024, Germany is expected to hold the largest share of the market, primarily driven by rising drug sales, support from government and regulatory authorities for biopharmaceuticals, and the expansion of manufacturing capacities by leading companies.

Quick Buy – Europe Single-use Bioreactors Market – Opportunity Analysis and Industry Forecast (2024-2030), Research Report: https://www.meticulousresearch.com/Checkout/77071228

Key Market Players
The Europe single-use bioreactors market features prominent players such as Merck KGaA (Germany), Danaher Corporation (U.S.), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Eppendorf AG (Germany), Solaris Biotechnology srl (Italy), Cellexus International Ltd. (U.K.), CESCO Bioengineering Co., Ltd. (Taiwan), PBS Biotech, Inc. (U.S.), Solida Biotech GmbH (Germany), and Infors AG (Switzerland).

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research